New hope for Hard-to-Treat cancers: first human trial launches
NCT ID NCT07159126
First seen Nov 01, 2025 · Last updated May 22, 2026 · Updated 27 times
Summary
This early-stage study tests a new drug called DS3610a in about 70 adults with advanced or metastatic solid tumors that have stopped responding to standard treatments. The main goal is to check the drug's safety and find the right dose. This is a first-in-human trial, so researchers are carefully monitoring for side effects and how the drug works in the body.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC SOLID TUMORS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
National Cancer Center Hospital
RECRUITINGChūōku, 104-0045, Japan
-
National Cancer Center Hospital East
RECRUITINGKashiwa, 277-8577, Japan
Conditions
Explore the condition pages connected to this study.